Complement-targeting therapies in hemolytic diseases.

Area of Science:

• Hematology
• Immunology
• Pharmacology

Background:

• Complement inhibition has transformed hemolytic disease management.
• Traditional therapies focused on terminal complement component 5 (C5) inhibition.
• Emerging strategies target earlier complement cascade components.

Purpose of the Study:

• To review recent advances in complement inhibition for hemolytic diseases.
• To highlight novel therapeutic agents targeting proximal complement pathways.
• To discuss personalized treatment approaches based on disease characteristics.

Main Methods:

• Review of recent clinical studies and therapeutic developments in complement inhibition.
• Analysis of novel complement inhibitors targeting C3, factor B, and factor D.
• Evaluation of treatment efficacy in paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and cold agglutinin disease.

Main Results:

• Newer agents like pegcetacoplan, iptacopan, and danicopan target proximal complement pathways.
• These agents effectively manage both intravascular and extravascular hemolysis.
• Oral and subcutaneous administration options are now available.
• Sutimlimab demonstrates efficacy in cold agglutinin disease by inhibiting the classical pathway.

Conclusions:

• The complement inhibitor landscape has expanded significantly, offering proximal and terminal pathway targeting.
• Innovations enable personalized treatment strategies for hemolytic conditions.
• Pathway-specific interventions optimize patient care and outcomes.